Abrégé

falciparumP. falciparumP. falciparum infection in a subject.

Classes IPC  ?

• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 33/06 - Antipaludéens

Abrégé

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

Classes IPC  ?

• C07K 14/55 - IL-2
• A61K 38/20 - Interleukines

Abrégé

The present invention relates to the use of modified dextran hydrogel microparticles comprising (i) at least one vinyl sulfone functionalized dextran, and (ii) at least one crosslinkable polymer having at least two thiol functions, wherein the dextran has a molecular weight comprised between 5 and 500 kDa, and the substitution degree of the dextran by the vinyl sulfone is comprised between 5 and 60%, for encapsulating at least one synthetic or natural cell. The present invention also relates to modified dextran hydrogel microparticles, a process for preparing them, an in vitro method for cultivating at least one cell comprised in said microparticles, in vitro methods for screening, for producing or for testing compounds, a kit, a microfluidic or millifluidic channel, a process for encapsulating said microparticles, and a method for the quality control of a batch. Said microparticles are useful in the field of biological and medical applications.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• A61K 9/50 - Microcapsules
• A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

Classes IPC  ?

• C07K 14/55 - IL-2

Abrégé

System (100), method and computer program product for training an encoder neural network (110) to generate stimulation patterns (192) for an auditory cortical implant having a predefined number of electrodes arranged in a two‐dimensional electrode array (220) adapted for use in mammals (201) with impaired hearing. The encoder processes soundwave training data records (210i) and outputs for each corresponding soundwave a one‐ dimensional encoded sound vector (191) which is mapped to the electrode array (220) to obtain corresponding two‐dimensional stimulation patterns (192) for the auditory cortical implant. A decoder neural network (130) reconstructs the respective training data record from the encoder output wherein the parameters of the decoder are determined in parallel to the encoder during training. A cost function with a first term (CFr) to measure reconstruction performance and a second term (CFc) to measure continuity of the stimulation patterns is used when training the encoder (110) and decoder (130 while aiming at minimizing a weighted sum of the terms (CFr, CFc) of the cost function.

Classes IPC  ?

• G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
• G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
• A61N 1/18 - Application de courants électriques par électrodes de contact
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques

Abrégé

The disclosure provides the structure of an MFSD2A-SYNC2 complex together with functional data that revealed important molecular aspects of MFSD2A transport cycle, receptor-mediated cell-cell fusion, and pharmacology and resulted in the identification of two novel allosteric modulators of MFSD2A, which are two soluble fragments of SYNC2, namely SYNC2su-co and SYNC2su-co-2, representing first-in-class molecules to inhibit MFSD2A LPCs uptake and increase transcytosis rate.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Provided are methods comprising expressing in a recombinant cell comprising a Cas gene a recombinant error-prone reverse transcriptase (RT) and a recombinant spacer RNA comprising a target sequence for mutagenesis of a DNA sequence in the Cas gene; making a mutagenized cDNA polynucleotide homologous to the DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence of the Cas gene in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant Cas protein, recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising the target sequence, and recombinant recombineering system.

Classes IPC  ?

• C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12N 9/22 - Ribonucléases
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants
• C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
• C40B 50/06 - Procédés biochimiques, p. ex. utilisant des enzymes ou des micro-organismes viables entiers

Abrégé

in vitroin vitroin vitro methods for screening, for producing or for testing compounds, a kit, a microfluidic or millifluidic channel, a process for encapsulating said microparticles, and a method for the quality control of a batch. Said microparticles are useful in the field of biological and medical applications.

Classes IPC  ?

• C08B 37/02 - DextraneSes dérivés
• C08J 3/075 - Gels macromoléculaires
• C08L 5/02 - DextraneSes dérivés
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse

Abrégé

The invention provides antibodies, and antigen-binding fragments thereof, that potently neutralize lyssavirus infection and the use of such antibodies. In particular, the invention provides methods of treatment of lyssavirus infection, such as rabies.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The invention relates to a new family of polymerases from archaeal viruses (PolARV) and their uses for nucleic acid synthesis, in particular untemplated nucleic acid synthesis.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

S. flexneriS. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and/or SFY.

Classes IPC  ?

• C07H 15/18 - Radicaux acycliques substitués par des carbocycles
• C07H 1/00 - Procédés de préparation des dérivés du sucre

Abrégé

The application generally relates to recombinant genetic constructs comprising a recombinant measles virus expressing at least one rubella virus polypeptide, protein, antigen, or antigenic fragment thereof, and one mumps virus polypeptide, protein, antigen, or antigenic fragment. The application also relates to the uses of genetic constructs or viruses, and more particularly their applications for inducing immune responses and protection against rubella infection, mumps infection, and measles infection.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a method for selecting lymphocytes recognizing a conformational epitope of a protein antigen from a population of cells, comprising a step of identifying at least one lymphocyte binding to at least two separate peptides comprising sequences of the protein antigen, in particular at least three separate peptides comprising sequences of the protein antigen.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/0781 - Cellules BLeurs progéniteurs
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• G01N 15/149 - Techniques de recherche optique, p. ex. cytométrie en flux spécialement adaptées au tri des particules, p. ex. selon leur taille ou leurs propriétés
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

Classes IPC  ?

• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

NPXNPXNPX in new methods for the efficient delivery of molecular cargos inside target cells (in particular neurons and eye retina cells). The invention further relates to a Neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof, in particular a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

Classes IPC  ?

• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Produits et services

Stem cells for medical and scientific research; stem cells other than for medical and veterinary use; cell growth media for growing and cultivating cells, intended for use in scientific and medical research; engineered human biological organoids for medical and scientific research; engineered non-human biological organoids for medical and scientific research; bacteriological preparations (other than for medical and veterinary use) for scientific research use, active chemical ingredients; microbial and human bioresources; microbial and human bioresources for medical and scientific research; diagnostic preparations other than for medical or veterinary use; diagnostic preparations for use in research laboratories; chemical active ingredients for the manufacture of pharmaceuticals; diagnostic biomarker reagents for medical and scientific research; organoids on a chip; organs on a chip; organoids on a chip or organs on a chip for medical and scientific research; cell culture preparations intended for use in scientific and medical research using tissue cultures in a microfluidic device. Pharmaceutical and veterinary products; vaccines; disinfectants, antibacterials, anti-allergens, sporicides, virucides, products for destroying vermin, fungicides, herbicides; antibiotics; amino acids for medical and veterinary use; adjuvants for medical and veterinary use; biological preparations for medical and veterinary use; bacteriological preparations for medical and veterinary use; diagnostic products for medical and veterinary use; insecticides; cultivating microorganisms for medical and veterinary use; stem cells, stem cells for medical and veterinary use; biological, clinical, viral or fungal tissues, molecules and bacteria for medical and veterinary use; drugs for medical and veterinary use; pesticides; pharmaceutical preparations and substances; medicinal preparations and substances; Pharmaceutical and veterinary products sold on prescription or over the counter; enzymes for medical and veterinary use; preparations of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical or veterinary use. Scientific research instruments and apparatus for laboratories; downloadable computer software applications; online downloadable applications, especially via an international telecommunications network on all media (such as a computer, mobile telephone, tablet); simulators; measuring apparatus, instruments and devices; weighing apparatus and instruments; optical apparatus and instruments; test benches (checking apparatus); diagnostic apparatus for use in research laboratories; software; software for processing, consulting, classifying, collaboratively exploiting, sharing, annotating and analyzing scientific and medical research images and data; artificial intelligence software; recorded computer programs; downloaded computer programs; online downloadable electronic publications, especially via the Internet on all media (such as a computer, mobile telephone, tablet); downloadable online scientific electronic publications particularly via the Internet on all media (such as computers, mobile telephones, tablets); databases; scientific databases; downloadable image files; downloadable image files for scientific research use; computer platforms in the form of recorded or downloadable software; computer platforms in the nature of recorded or downloadable software for scientific and medical research; interfaces (for computers); computer interfaces for scientific and medical research; medical imaging software; software intended for use in tracking medical, biological, scientific and veterinary analyses; downloadable software applications intended for use in tracking medical, biological, scientific and veterinary analyses. Printing products (printed matter); photographs; instructional or teaching material in the scientific or medical field (except apparatus); printing blocks; printed matter, newspapers, periodicals, journals; printed matter, newspapers, periodicals, journals of a scientific or medical nature; albums; pamphlets; notebooks; catalogs; forms, printed; engravings, pictures, prints; books; handbooks [manuals]; publications; posters; leaflets; albums, brochures, notebooks, catalogs, forms, engravings, images, prints, books, manuals, publications, posters and leaflets of a scientific or medical nature. Advertising; bill-posting; creation of advertising material; distribution of advertising material [leaflets, prospectuses, printed matter, samples, derivatives]; distribution of advertising material [leaflets, prospectuses, printed matter, samples, derivatives]; dissemination of advertisements; advertisement dissemination; Promoting research (advertising); administrative and/or commercial services with respect to contracts for the transfer of innovation, technology, research results and intangible assets, advice relating thereto; market studies; business auditing (commercial analysis); administrative and/or commercial services with respect to research, negotiating, steering and coordinating research, institutional, industrial or commercial cooperation or partnerships, between industrial players, inventors and research centers; administrative and/or commercial services with respect to steering and coordinating the transfer and exchange of innovation, technology, research results; administrative and/or commercial services with respect to the management of research programs, innovation, technology, research results; public relations; commercial lobbying; sponsorship search; business networking; distribution of promotional material; acquisition, management, organization, administration, compilation, processing, systematization and update of data and databases; computer file management; compiling statistical data intended for use in scientific and medical research; corporate management assistance in the field of health, namely: assistance in business organization and general administration; news clipping services; compilation of statistics; retail services for downloadable image files of a scientific and medical nature; promoting public awareness in the field of health and medical research through awareness and information programs. Organizing collections of gifts for scientific and medical research; charitable fundraising for scientific and medical research; fundraising for scientific and medical research; information with respect to fundraising for scientific and medical research; information with respect to gifts for scientific and medical research; financial patronage operations; financial sponsorship for philanthropic purposes for scientific and medical research; funding searches; equity search; funding research and development projects; capital raising and capital raising negotiation services; investment search, investment management, financial investment services in the field of health and medical and scientific research; Real property management service. Education, teaching, tuition; training; cultural activities; scientific teaching; publishing of scientific works; film production; organization and conducting of colloquiums; organization and conducting of conferences, congresses; organization of exhibitions for cultural or educational purposes; organization of contests; publication of books; museum services (presentations, exhibitions); photography; information on education; videotaping; provision of non-downloadable videos online; tutoring; electronic desktop publishing; practical training; book lending; film projections; organization and conducting of seminars; organization and conducting of symposiums; training with respect to health; scientific training sessions; publishing scientific articles and specialist scientific information journals; editing, drafting reports and writing scientific texts; publication of scientific articles; organizing competitions in the scientific field; education, teaching and instruction services in the field of medicine, public health and scientific research; providing online seminars and training courses and online non-downloadable videos in the field of scientific and medical research; organization of competitions and award ceremonies. Research services, development in the industrial, scientific, medical, pharmaceutical and biological field; clinical studies (trials); scientific laboratory services; scientific analyses; developing diagnostic methods, namely services for developing medical diagnostic methods; development of new products for others, namely products or materials intended for use in patient care paths, diagnoses, prognostics or therapy; laboratory services, namely, providing laboratory analysis services in the medical, pharmaceutical, biological and veterinary fields; conducting scientific investigations for medical purposes to establish the origin of disease onset; scientific consultation and research services namely designing, conducting and managing research projects in the medical, pharmaceutical, biological and veterinary fields; research and consultation services in the medical, pharmaceutical, veterinary and biological fields; bacteriological and chemical laboratories; industrial and scientific research and analyses for medical, pharmaceutical, veterinary, biological purposes; developing, designing and updating software, computer programming, reconstitution of databases; research in the field of artificial intelligence; research laboratories; development of testing methods; scientific research and development; scientific study services; designing and developing monitoring, diagnostic, forecasting and analysis tools; electronic data storage; rental of downloadable image files of a scientific and medical nature; stem cell research; cell culture for scientific research purposes; research and development in the field of microorganisms and cells; research and development in the field of organoids and organs on a chip; analyses, testing and trial services for human tissue, cells, molecules and biological, clinical, viral, bacterial or fungal materials; scientific services relating to the isolation and cultivation of human tissues and cells; research and development in the field of microorganisms and cells; service for the storage, characterization and provision of biological resources; service for the storage, characterization and provision of biological resources for medical and scientific research purposes; hosting platforms on the Internet, hosting Web portals, temporary provision of non-downloadable software applications accessible via an Internet site; collaborative platform design services in the field of medical research and health; providing temporary use of non-downloadable computer software enabling users to enter, access, track, check and generate medical, biological, bacteriological, scientific and chemical information, analysis and reports; creation of databases. Medical services; medical analysis laboratory services; health services; consultation services with respect to medicine, pharmacy or bacteriology or virology in the field of human or animal health; medical screening; storing of human cells for medical use (biomedical services); provision of medical information; medical analysis services; providing medical, healthcare and medical services information on any medium, including online via the Internet and social networks; provision of advice, medical care and health services online on the Internet or on social networks; medical services, namely medical diagnostic, assessment, analysis services; medical assistance services; genetic analysis for medical use; medical examination services for individuals; vaccination services; medical analyses.

Abrégé

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Ala- N-Methyl-L-Val- L-Ala-OMe, or a variant thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) SI-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response of infected animals. The invention is also directed to a exhaustive signature of Map and a mass spectrometry signature of Map presence or infection.

Classes IPC  ?

• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• C07K 5/083 - Tripeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala

Abrégé

Schistosoma haematobium, Opisthorchis viverriniSchistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis and provide evidence of fluke-borne infection of parasitized vertebrate hosts.. The invention provides viruses, nucleic acids, proteins, peptides, and antibodies useful for diagnosis, treatment, and prevention of viral infection and associated diseases.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I). The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/52 - Purines, p. ex. adénine
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
• C07D 471/04 - Systèmes condensés en ortho
• C07D 473/00 - Composés hétérocycliques contenant des systèmes cycliques purine
• C07D 473/40 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'halogènes ou des radicaux perhalogénoalkyles liés directement en position 2 ou 6
• C07D 487/04 - Systèmes condensés en ortho
• C07D 495/04 - Systèmes condensés en ortho

Abrégé

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.

Classes IPC  ?

• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 31/04 - Agents antibactériens
• C12N 9/50 - Protéinases
• C12N 9/52 - Protéinases provenant de bactéries

Abrégé

A recombinant lentiviral vector genome comprising a polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide comprises, arranged from N-terminal to C-terminal ends: a first polypeptide comprising (i) an MHC-ll-associated light invariant chain (li), or (ii)) the transmembrane domain of the transferrin receptor (TfR) and at least one antigenic polypeptide of a pathogen. The invention also relates to a lentiviral vector and pharmaceutical compositions comprising it.

Classes IPC  ?

• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/09 - Cellules tumorales
• C12N 15/86 - Vecteurs viraux

Abrégé

Here, the inventors use genomics to discover a new family of lanthipeptides from Actinobacteria dedicated to anti-phage defense. They demonstrate that a specific family of metabolic pathways that produce unknown class I lanthipeptides are encoded near known anti-phage defense systems or within mobile genetic elements, indicating their anti-phage function. Furthermore, the inventors show that the heterologous expression of these pathways in Streptomyces albus (a model strain of Actinobacteria) confers anti-phage defense. The experimental results show that different lanthipeptides of this family confer a selective protection against phages, without compromising the cell viability. The inventors also have identified a specific regulatory system that controls the expression of "defensive lanthipeptides" in Actinobacteria and use this to demonstrate their anti-phage function in a native strain. Finally, the inventors explore the anti-phage mechanism of action of these compounds. Thus the present invention relates to a new class of anti-phage natural peptides.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 7/54 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle

Abrégé

Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or Alzheimer's disease-related origin. Compositions, in particular, an oral composition, including the Lachnospiraceae spp and Ruminococcus lactaris strains and uses thereof.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A01K 67/0278 - Vertébrés knock-in, p. ex. vertébrés humanisés
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The invention relates to ApsA and ApsB proteins, including ApsA-like and ApsB-like proteins, and to their involvement in the mobilisation of the carbapenemase blaOXA-48 gene from the pOXA-48 plasmid into the chromosome. The ApsA and ApsB proteins combine a nuclease/helicase protein and a novel type of Argonaute-like protein to cleave DNA. The invention encompasses compositions comprising ApsA and ApsB proteins, including ApsA-like and ApsB- like proteins, antibodies against these proteins, nucleic acids encoding these proteins, vectors expressing these proteins and cells and kits comprising these nucleic acids, vectors and/or proteins. The invention further encompasses methods for making and using these compositions for diagnostic assays and for genetic engineering.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 1/08 - Réduction de la teneur en acide nucléique
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention relates to the human protein Family with sequence similarity 118 member B (FAM118B). In particular, the present invention relates to the activation, or the inhibition of the activity or effect provided by FAM118B, for modulating the inflammatory response. In particular, it is provided the use of activator of FAM118B, or an activator of the biological effects provided by FAM118, for inducing, sustaining, or enhancing an inflammatory process, in particular an inflammatory process associated with a cancer, a bacterial infection, or a viral infection. In particular, it is also provided the use of an inhibitor of FAM118B, or an inhibitor of the biological effects provided by FAM118B, for inhibiting, or reducing an inflammatory process, more particularly for inducing the resolution of an inflammatory process.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Produits et services

Pharmaceutical and veterinary products; vaccines; disinfectants, antibacterials, anti-allergens, sporicides, virucides, products for destroying vermin, fungicides, herbicides; antibiotics; amino acids for medical and veterinary use; adjuvants for medical and veterinary use; biological preparations for medical and veterinary use; bacteriological preparations for medical and veterinary use; diagnostic products for medical and veterinary use; insecticides; cultivating microorganisms for medical and veterinary use; stem cells, stem cells for medical and veterinary use; biological, clinical, viral or fungal tissues, molecules and bacteria for medical and veterinary use; drugs for medical and veterinary use; pesticides; pharmaceutical preparations and substances; medicinal preparations and substances; Pharmaceutical and veterinary products sold on prescription or over the counter; enzymes for medical and veterinary use; preparations of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical or veterinary use Organizing collections of gifts for scientific and medical research; charitable fundraising for scientific and medical research; fundraising for scientific and medical research; information with respect to fundraising for scientific and medical research; information with respect to gifts for scientific and medical research; financial patronage operations; financial sponsorship for philanthropic purposes for scientific and medical research; funding searches; equity search; funding research and development projects; capital raising and capital raising negotiation services; investment search, investment management, financial investment services in the field of health and medical and scientific research; Real property management service Education, teaching, tuition; training; cultural activities; scientific teaching; publishing of scientific works; film production; organization and conducting of colloquiums; organization and conducting of conferences, congresses; organization of exhibitions for cultural or educational purposes; organization of contests; publication of books; museum services (presentations, exhibitions); photography; information on education; videotaping; provision of non-downloadable videos online; tutoring; electronic desktop publishing; practical training; book lending; film projections; organization and conducting of seminars; organization and conducting of symposiums; training with respect to health; scientific training sessions; publishing scientific articles and specialist scientific information journals; editing, drafting reports and writing scientific texts; publication of scientific articles; organizing competitions in the scientific field; education, teaching and instruction services in the field of medicine, public health and scientific research; providing online seminars and training courses and online non-downloadable videos in the field of scientific and medical research; organization of competitions and award ceremonies Research services, development in the industrial, scientific, medical, pharmaceutical and biological field; clinical studies (trials); scientific laboratory services; scientific analyses; developing diagnostic methods, namely services for developing medical diagnostic methods; development of new products for others, namely products or materials intended for use in patient care paths, diagnoses, prognostics or therapy; laboratory services, namely, providing laboratory analysis services in the medical, pharmaceutical, biological and veterinary fields; conducting scientific investigations for medical purposes to establish the origin of disease onset; scientific consultation and research services namely designing, conducting and managing research projects in the medical, pharmaceutical, biological and veterinary fields; research and consultation services in the medical, pharmaceutical, veterinary and biological fields; bacteriological and chemical laboratories; industrial and scientific research and analyses for medical, pharmaceutical, veterinary, biological purposes; developing, designing and updating software, computer programming, reconstitution of databases; research in the field of artificial intelligence; research laboratories; development of testing methods; scientific research and development; scientific study services; designing and developing monitoring, diagnostic, forecasting and analysis tools; electronic data storage; rental of downloadable image files of a scientific and medical nature; stem cell research; cell culture for scientific research purposes; research and development in the field of microorganisms and cells; research and development in the field of organoids and organs on a chip; analyses, testing and trial services for human tissue, cells, molecules and biological, clinical, viral, bacterial or fungal materials; scientific services relating to the isolation and cultivation of human tissues and cells; research and development in the field of microorganisms and cells; service for the storage, characterization and provision of biological resources; service for the storage, characterization and provision of biological resources for medical and scientific research purposes; hosting platforms on the Internet, hosting Web portals, temporary provision of non-downloadable software applications accessible via an Internet site; collaborative platform design services in the field of medical research and health; providing temporary use of non-downloadable computer software enabling users to enter, access, track, check and generate medical, biological, bacteriological, scientific and chemical information, analysis and reports; creation of databases Medical services; medical analysis laboratory services; health services; consultation services with respect to medicine, pharmacy or bacteriology or virology in the field of human or animal health; medical screening; storing of human cells for medical use (biomedical services); provision of medical information; medical analysis services; providing medical, healthcare and medical services information on any medium, including online via the Internet and social networks; provision of advice, medical care and health services online on the Internet or on social networks; medical services, namely medical diagnostic, assessment, analysis services; medical assistance services; genetic analysis for medical use; medical examination services for individuals; vaccination services; medical analyses

Produits et services

(1) Produits pharmaceutiques et vétérinaires; vaccins; désinfectants, antibactériens, anti-allergènes, sporicides, virucides, produits pour la destruction d'animaux nuisibles, fongicides, herbicides; antibiotiques; aminoacides à usage médical et vétérinaire; adjuvants à usage médical et vétérinaire; préparations biologiques à usage médical et vétérinaire; préparations bactériologiques à usage médical et vétérinaire; produits pour le diagnostic à usage médical et vétérinaire; insecticides; culture de micro-organismes à usage médical et vétérinaire; cellules souches, cellules souches à usage médical et vétérinaire; tissus, molécules et bactéries biologiques, cliniques, virales ou fongiques à usage médical et vétérinaire; drogues à usage médical et vétérinaire; pesticides; substances et préparations pharmaceutiques; substances et préparations médicinales; produits pharmaceutiques et vétérinaires vendus sur ordonnance ou en vente libre; enzymes à usage médical et vétérinaire; préparations de micro-organismes à usage médical ou vétérinaire; réactifs de biomarquage pour le diagnostic à usage médical ou vétérinaire. (1) Organisation de collectes de dons pour la recherche scientifique et médicale; collecte de bienfaisance pour la recherche scientifique et médicale; collecte de fonds pour la recherche scientifique et médicale; informations en matière de collecte de fonds pour la recherche scientifique et médicale; informations en matière de dons pour la recherche scientifique et médicale; opérations de mécénat financier; parrainage financier à but philanthropique pour la recherche scientifique et médicale; recherches de financements; recherche de capitaux propres; financement de projets de recherches et développement; services de levées de capitaux et de négociations de levées de capitaux; recherche d'investissement, gestion d'investissement, services financiers d'investissement dans le domaine de la santé et de la recherche médicale et scientifique; service de gestion de biens immobiliers. (2) Education, enseignement, instruction; formation; activités culturelles; enseignement scientifique; édition d'ouvrages scientifiques; production de films; organisation et conduite de colloques; organisation et conduite de conférences, congrès; organisation d'expositions à buts culturels ou éducatifs; organisation de concours; publication de livres; services de musées (présentations, expositions); photographie; information en matière d'éducation; enregistrement (filmage) sur bande vidéo; mise à disposition en ligne de vidéos non téléchargeables; tutorat; micro-édition; formation pratique; prêt de livres; projections de films; organisation et conduite de séminaires; organisation et conduite de symposiums; formations en matière de santé; formations scientifiques; services de publication d'articles scientifiques et de revues spécialisées en information scientifique; édition, établissement de rapports et rédaction de textes scientifiques; publication d'articles scientifiques; organisation de concours dans le domaine scientifique; services d'éducation, d'enseignement et d'instruction dans le domaine médical, de la santé publique et de la recherche scientifique; mise à disposition de séminaires et de cours de formation en ligne et par vidéos en ligne non téléchargeables dans le domaine de la recherche scientifique et médicale; organisation de concours et de cérémonies de remise de prix. (3) Services de recherche, de développement dans le domaine industriel, scientifique, médical, pharmaceutique, biologique; études (essais) cliniques; services de laboratoires scientifiques; analyses scientifiques; élaboration de méthode de diagnostic, à savoir services de développement de méthodes de diagnostic médical; développement de nouveaux produits pour des tiers à savoir produits ou matériels destinés à être utilisés dans le cadre du parcours de soin des patients, du diagnostic, du pronostic ou thérapeutique; services de laboratoires, à savoir, fourniture de services d'analyses de laboratoire de dans les domaines médical, pharmaceutique, biologique et vétérinaire; conduite d'investigations scientifiques à des fins médicales pour établir l'origine du déclenchement des maladies; services de consultation scientifique et de recherche à savoir conception, conduite et gestion de projets de recherche dans les domaines médical, pharmaceutique, biologique et vétérinaire; services de recherches et de consultations dans les domaines médical, pharmaceutique, vétérinaire, biologique; laboratoires bactériologiques et chimiques; recherches et analyses industrielles et scientifiques à but médical, pharmaceutique, vétérinaire, biologique; élaboration, conception et mise à jour de logiciels, programmation pour ordinateur, reconstitution de bases de données; recherche dans le domaine de l'intelligence artificielle; laboratoires de recherche; développement de méthodes d'essai; recherche et développement scientifique; services d'études scientifiques; conception et développement d'outils de suivi, de diagnostic, de prédiction et d'analyse; stockage électronique de données; service de location de fichiers d'images téléchargeables à caractère scientifique et médical; recherche sur les cellules souches; culture de cellules à des fins de recherche scientifique; recherche et développement dans le domaine des micro-organismes et cellules; recherche et développement dans le domaine des organoïdes et organes à puces; service d'analyses, de tests et d'essai de tissus humains, de cellules, molécules et de matériel biologique, clinique, viral, bactérien ou fongique; services scientifiques en matière d'isolement et de culture de cellules et tissus humains; recherche et développement dans le domaine des micro-organismes et des cellules; service de stockage, caractérisation et mise à disposition de ressources biologiques; service de stockage, caractérisation et mise à disposition de ressources biologiques à des fins de recherche médicale et scientifique; plateformes d'hébergement sur internet, hébergement de portails web, mise à disposition temporaire d'applications logicielles non téléchargeables accessibles par le biais d'un site internet; services de conception de plateformes collaboratives dans le domaine de la recherche médicale et de la santé; mise à disposition temporaire de logiciels informatiques non téléchargeables permettant aux utilisateurs d'entrer, d'accéder, de suivre, de contrôler et de générer des informations, des analyses et des rapports médicaux, biologiques, bactériologiques, scientifiques et chimiques; création de bases de données. (4) Services médicaux; services de laboratoires d'analyse médicale; services de santé; services de consultation en matière de médecine, de pharmacie ou de bactériologie ou virologie dans le domaine de la santé humaine ou animale; dépistage médical; entreposage de cellules humaines à usage médical (services biomédicaux); mise à disposition d'informations médicales; services d'analyses médicales; fourniture de renseignements médicaux, de soins de santé et de services médicaux sur tout support, y compris en ligne par le biais d'internet et des réseaux sociaux; fourniture de conseils, de soins médicaux et de services de santé en ligne sur Internet ou sur les réseaux sociaux; services médicaux, à savoir services de diagnostics, d'évaluations, d'analyses médicales; services d'assistance médicale; analyses génétiques à usage médical; services d'examen médical pour particuliers; services de vaccination; analyses médicales.

Produits et services

Pharmaceutical and veterinary preparations; Vaccines; Disinfectants, antibacterials, anti-allergens, sporicides, virucides, products for destroying of damaging animals, fungicides, herbicides; Antibiotics; Amino acids for medical and veterinary purposes; adjuvants used for medical and veterinary uses; Biological preparations for medical and veterinary purposes; Bacteria preparations for medical and veterinary purposes; Diagnostic preparations for medical and veterinary purposes; Insecticides; Cultures of microorganisms for medical and veterinary uses; Stem cells, Stem cells for medical and veterinary purposes; Biological, clinical, viral or fungal tissues, molecules and bacteria For medical and veterinary uses; Drugs for medical purposes and Drugs for veterinary use; Pesticides; Pharmaceutical preparations and substances; Medicinal preparations and substances; Enzymes for medical and veterinary purposes; Preparations of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical or veterinary use. Arranging of donation collections for scientific and medical research; Charitable fundraising for scientific and medical research; Fundraising for scientific and medical research; Information on fundraising for scientific and medical research; Information on donations for scientific and medical research; Financial sponsorship; Financial sponsorship for philanthropic purposes for scientific and medical research; Fundraising; Equity research; Financing of research and development projects; Capital raising and capital raising negotiation; Investment research, investment management, financial investment in the field of health and of medical and scientific research; Real-estate management services. Education, teaching, tuition; Training; Conducting of cultural activities; Scientific instruction; Publishing of scientific works; Film production services; Arranging and conducting of colloquiums; Arranging and conducting of conferences and congresses; Arranging of exhibitions for cultural or educational purposes; Arranging of contests; Publication of books; Museum facilities (Providing -) [presentation, exhibitions]; Photography; Information (education-); Videotaping; Providing online videos, not downloadable; Tutoring; Electronic desktop publishing; Practical training [demonstration]; Lending library services; Film screenings; Arranging and conducting of seminars; Arranging and conducting of symposiums; Providing of training on health; Scientific training; Publishing of scientific articles and specialised journals in scientific information; Publishing, reporting and writing of scientific texts; Publishing of scientific papers; Arranging of contests In the scientific field; Teaching, Teaching and Teaching In the medical, public health and scientific research field; Providing of seminars and training courses online and via online non-downloadable videos in the following fields: Scientific and medical research; Organisation of competitions and award ceremonies. Research and development in the industrial, scientific, medical, pharmaceutical and biological fields; Clinical trials; Scientific laboratory services; Scientific analysis; Development of diagnostic methods, namely Development of medical diagnostic methods; Development of new products, for others, namely goods or materials for use in the context of care pathways for patients, diagnosis, prognosis or therapy; Laboratory services, namely Laboratory analysis in the medical, pharmaceutical, biological and veterinary field; Conducting of scientific investigations for medical purposes to establish the origin of diseases; Scientific consultation and research, namely Design, conducting and management of research projects in the medical, pharmaceutical, biological and veterinary field; Research In the medical, pharmaceutical, veterinary and biological field; Advice and information In the field of biology; Bacteriological and chemical laboratories; Industrial analysis and research services For medical, pharmaceutical, veterinary, biological purposes; Design and updating of software, Computer programming, Recovery of computer data; Research in the field of artificial intelligence technology; Research laboratories; Development of testing methods; Scientific research and development; Provision of surveys [scientific]; Design and development of monitoring, diagnostic, predictive and analytical tools; Electronic data storage; Rental of downloadable scientific and medical images; Stem cell research; Culturing of cells for scientific research purposes; Research and development in the field of microorganisms and cells; Research and development In the field of organoids and organs-on-a-chip; Analysis, testing and trial of human tissues, cells, molecules and biological, clinical, viral, bacterial or fungal materials; Scientific services relating to the isolation and cultivation of human tissues and cells; Research and development in the field of microorganisms and cells; Storage, characterisation and providing of biological resources; Storage, characterisation and providing of biological resources For scientific and medical research purposes; Internet hosting platforms, web portal hosting, providing of temporary use of non-downloadable computer software applications accessible via a website; Design of collaborative platforms in the medical and health field; Providing of temporary use of non-downloadable computer software enabling users to enter, access, track, control and generate medical, biological, bacteriological, scientific and chemical information, analysis and reports. Medical services; Medical laboratory analysis; Medical services; Consultancy relating to medicine, pharmacy, bacteriology or virology in the field of human or animal health; Medical screening; Biomedical services, namely, the storage of human cells for medical use; Providing medical information; Medical analysis services; Providing of medical intelligence, healthcare and medical services on media of all kinds, including online via the internet and social networks; Providing of advice, medical care and healthcare services online on the internet or via social networks; Awareness and information schemes In the field of health and medical research; Medical services, namely medical diagnosis, evaluations, medical analysis; Medical assistance; Genetic testing for medical purposes; Medical examination of individuals; Vaccination services; advising In the medical, pharmaceutical and veterinary field; Medical analysis.

Abrégé

1234523231677 represent independently a hydrogen or a methyl; - wherein n and m are integers, independently selected among 1 to 3; and - wherein p is an integer selected among 1 and 2.

Classes IPC  ?

• C07D 221/20 - Systèmes cycliques condensés en spiro
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 35/00 - Agents anticancéreux
• A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle

Abrégé

A dual AAV vector strategy encoding isoform 5 of otoferlin cDNA that has been split into two expression cassettes both packaged in—and delivered by—an AAV8 capsid can efficiently deliver the otoferlin cDNA to the inner hair cell (IHC). Moreover, the use of the CMV promoter in one of the two AAV8 vectors provides a significant expression of otoferlin in these particular cells. As the AAV serotype and the type of promoter used are two key elements that have a significant effect on the transduction efficiency, this vector system provides optimal therapeutic benefit in patients suffering from DFNB9 deafness. To further improve this therapeutic effect, otoferlin-encoding dual vector constructs to identify enhanced transfection rate and a very effective in vitro and in vivo otoferlin expression in mature cochlea of DFNB9 mice models, leading to the restoration of their hearing.

Classes IPC  ?

• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 27/16 - Otologiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to an engineered DNA polymerase D (PolD) and its use for nucleic acid amplification including reverse transcription of RNA.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques

Abrégé

The invention relates to nucleic acid constructs which comprises a DNA molecule encoding a recombinant L or S segment of a Mopeia virus (MOPV), as well as an expression cassette or a vector comprising them, an eukaryotic cell comprising them, and a method of expressing one or more polypeptide(s) or protein(s) that is(are) heterologous to Mopeia virus (MOPV) or fragments thereof and/or producing recombinant live attenuated Mopeia virus (MOPV) expressing one or more polypeptide(s) or protein(s) that is(are) heterologous to MOPV or fragments thereof, in a eukaryotic host cell, using in particular the nucleic acid constructs of the invention. The invention also relates to a composition comprising viral particles obtained from such a method, a viral particle obtained from such a method and a set of nucleic acid constructs or expression cassettes or vectors comprising them, wherein the set comprises at least one nucleic acid construct or expression cassette or vector comprising it, which encodes a recombinant L segment of a Mopeia virus (MOPV), and one nucleic acid construct or expression cassette or vector comprising it, which encodes a recombinant S segment of a Mopeia virus (MOPV) that encodes a MOPV nucleoprotein (NP) having attenuated exonuclease activity, wherein one or both nucleic acid constructs or expression cassettes or vectors comprise(s) a polynucleotide encoding a polypeptide or a protein that is heterologous to MOPV and the latter is different from a non-MOPV GPC when on the S segment, and wherein the positions where the polynucleotide encoding at least one polypeptide or protein that is heterologous to MOPV is inserted in the said nucleic acid constructs or expression cassettes or vectors are peculiar.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/86 - Vecteurs viraux
• A61K 39/12 - Antigènes viraux

Abrégé

The invention relates to the field of cancer therapy, especially by inducing cell death of malignant B cells by activating RIPK3 signaling pathway in these cells. The invention thus involves activating RIPK3 signaling pathway in malignant B cells for treating a patient in need thereof. The activation of RIPK3 signaling pathway in malignant B cells has in particular been shown to be beneficial against tumor growth, in particular when combined with an agonist of MLKL (like type I IFN) and/or a caspase inhibitor that optimize direct tumor cell death and subsequent anti-tumor immune response.

Classes IPC  ?

• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 31/404 - Indoles, p. ex. pindolol
• A61K 38/21 - Interférons
• A61K 38/45 - Transférases (2)
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

Plasmodium falciparum50Plasmodium falciparum50P. falciparum50P. falciparum5050 value= 0.99 µM. The present invention thus relates to the use of ravidasvir, velpatasvir, and elbasvir for blocking transmission of Plasmodium gametocytes.

Classes IPC  ?

• A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
• A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
• A61K 31/47 - QuinoléinesIsoquinoléines
• A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/525 - Iso-alloxazines, p. ex. riboflavines, vitamine B2
• A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
• A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
• A61K 31/65 - Tétracyclines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 33/06 - Antipaludéens

Abrégé

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention relates to antibodies against Severe Acute Respiratory Syndrome -related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli

Abrégé

The invention concerns a multivalent immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV), wherein each valence is constituted by a recombinant live attenuated Mopeia virus in which the MOPV nucleoprotein (NP) has attenuated exonuclease activity and the encoded glycoprotein precursor (GPC) is from a New World arenavirus selected from one of the following arenaviruses: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV). The invention also concerns a combination of active ingredients, a composition or vaccine, or a therapeutically effective composition, comprising such recombinant live attenuated Mopeia viruses (MOPV) for use in eliciting a protective immune response in a mammalian host against a New World arenavirus infection. The invention also concerns a method of preparing such recombinant live attenuated Mopeia viruses (MOPV) in a eukaryotic host cell and a method of preparing a multivalent, in particular a pentavalent, immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV) expressing a GPC protein of a New World arenavirus selected among: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV).

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

A composition comprising an oil phase comprising notably a botanical extract and an oil in water emulsion comprising said composition. The composition can include one or more non-VOC bio-based solvents chosen from the group of esters of aliphatic monocarboxylic acids, two or more bio-based non-ionic surfactants, and an anti-foaming agent. It further relates to the use of such composition and emulsion as an insecticidal agent, in particular a larvicidal agent.

Classes IPC  ?

• A01N 65/24 - Lauraceae [famille du laurier], p. ex. laurier, avocat, sassafras, cannelle ou camphre
• A01N 25/04 - Dispersions ou gels
• A01N 25/30 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles caractérisés par les agents tensio-actifs
• A01N 43/08 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• A01P 7/04 - Insecticides

Abrégé

The invention relates to immunocytokines comprising an anti-CTLA-4 antibody fused to a Treg-specific IL-2 receptor antagonist and their use to selectively deplete tumor-associated Tregs, in particular for treating cancer.

Classes IPC  ?

• A61K 38/20 - Interleukines
• C07K 14/55 - IL-2
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Clostridioides difficileClostridioides difficile.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation

Abrégé

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The invention relates to a method for reprogramming CD8+ T cells to enhance their therapeutic potential and its applications, in particular in adoptive T cell therapy for the treatment of infectious diseases and cancer.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides

Abrégé

The present invention relates to anti-ACE2 peptidase domain single domain antibodies. Further, the present invention relates to anti-ACE2 single domain antibodies comprising the CDR regions of the present single domain antibodies, polypeptides comprising thereof such as multimers thereof, and fusion proteins comprising thereof, as well as pharmaceutical compositions comprising the single domain antibodies, the polypeptides comprising thereof such as the multimeric single domain antibodies thereof, or the fusion proteins comprising thereof, and their use for treating diseases caused by a virus having ACE2 as receptor.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The invention relates to the field of immunity against coronaviruses. In this respect, the invention provides a lentiviral-based immunogenic agent that is suitable for use in boost or target immunization treatment in a subject, in particular a human subject, who had previously developed an immunity against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) based on: (i) vaccination with the first generation of vaccines against SARS-CoV-2 infection or disease such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine composition against SARS-CoV-2 infection or disease, in particular a protein- or an mRNA-based vaccine, or (ii) SARS-CoV-2-induced or correlated disease. The invention accordingly concerns a lentiviral-based immunogenic agent that in particular may help overcome the deficiencies of available vaccines against SARS-CoV-2, especially may be efficient in overcoming the waning immune response or insufficient cellular memory response observed after immunization with available first generation of vaccines such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine, in particular protein or mRNA vaccine, by triggering a mucosal humoral and cellular immune response against coronaviruses, including a long-lasting immune response.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants

Abrégé

A method for genotyping a plasmodium comprising: (a) providing a sample containing a Plasmodium; and (b) detecting the presence of an increased copy number of the genomic plasmepsin2-3 cluster. A method for the detection of a plasmodium infection in a patient comprising: (a) providing a blood sample from a patient and (b) detecting the presence or absence of an increased copy number of the genomic plasmepsin2-3 cluster in the blood sample. Kits for genotyping a plasmodium and/or detection of a plasmodium infection. Methods of treating a plasmodium infection.

Classes IPC  ?

• C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires
• C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme

Abrégé

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides

Abrégé

The present invention relates to an in vitro method for analyzing DNA interactions and kits for implementing said method. The method of the invention is more particularly useful for analyzing interactions between i) single-strand DNA (ssDNA) and ii) double-strand or single- strand DNA (dsDNA or ssDNA).

Classes IPC  ?

• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]

Abrégé

The invention discloses a lentiviral vector and lentiviral vector particles for treating hepatitis B infection. The lentiviral vector and particles of the invention contain a nucleotide sequence coding an hepatitis B virus antigen. The large S antigen of hepatitis B virus was in particular selected as candidate and can be applied in pharmaceutical compositions or vaccines for treating and/or preventing hepatitis B virus infection or treating and/or preventing diseases caused by hepatitis B virus infection, which has excellent therapeutic and preventive effects in subjects in need thereof.

Classes IPC  ?

• A61K 39/29 - Virus de l'hépatite
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

A medical device for the delivery of a therapeutic agent by bioprinting including a rod body including a bioprinting cartridge arranged near the distal end of the rod body including a top layer including a solution containing a therapeutic agent; and an absorbent compound capable of converting light energy from laser radiation into thermal energy and arranged to cause heating of the solution including a therapeutic agent to cause a jet of the solution; an optical fiber extending longitudinally within a lumen of the rod body to deliver laser flow onto the absorbing compound.

Classes IPC  ?

• A61M 25/00 - CathétersSondes creuses

Abrégé

A recombinant lentiviral vector comprising a coding sequence for an OR protein fused to a coding sequence for a fluorescent protein or a subunit of a fluorescent protein, and a promoter active in human cells operatively linked to the coding sequences. A recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription. A recombinant eukaryotic cell comprising a genomically integrated DNA copy of the recombinant lentiviral vector. A method of observing lentiviral DNA in a eukaryotic cell, comprising: providing a recombinant eukaryotic cell that produces a fusion protein comprising an OR protein, fused to a fluorescent protein or a subunit of a fluorescent protein: infecting the recombinant eukaryotic cell with a recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription, under conditions sufficient for reverse transcription of the recombinant lentiviral genome comprising an ANCH sequence: allowing the OR protein to bind to the ANCH sequence; and detecting the fluorescent protein or subunit of the fluorescent protein to thereby observe the lentiviral DNA in the eukaryotic cell. This tool can be suitable also for in vivo applications (e.g. humanized mice) as well as for screening of new antiretroviral compounds. The HIV-1 ANCHOR system can be extended to the study of other viruses or for the screening of antiviral compounds, e.g. against SARS-COV2.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 15/86 - Vecteurs viraux

Abrégé

An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61P 37/08 - Agents antiallergiques

Abrégé

The invention relates to a microfluidic device (10) comprising: - a support (20) comprising a substrate (25) made of an elastically deformable material; - a study chamber (30, 30a, 30b) extending inside the support (20) having at least one upper wall (32) at least partially formed by the substrate (25), at least one lower wall (34) and at least two side walls (33); - at least one substrate deformation chamber (40, 40a, 40b) at least partially formed by the substrate (25), fluidically independent of the study chamber (30, 30a, 30b) and at least partially extending inside the support (20) along one of the side walls (33) of the study chamber (30), the device being configured so that the deformation of the deformation chamber (40, 40a, 40b) causes the mechanical straining of at least one portion of the upper wall (32) in the study chamber (30).

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

The invention concerns a method implemented by computer means for visualizing at least a zone of an object in at least one interface, said method comprising the following steps: obtaining at least one image of said zone, said image comprising at least one channel, said image being a 2-dimensional or 3-dimensional image comprising pixels or voxels, a value being associated to each channel of each pixel or voxel of said image, a representation of said image being displayed in the interface, obtaining at least one annotation from a user, said annotation defining a group of selected pixels or voxels of said image, calculating a transfer function based on said selected pixels or voxels and applying said transfer function to the values of each channel of the image, updating said representation of the image in the interface, in which the colour and the transparency of the pixels or voxels of said representation are dependent on the transfer function.

Classes IPC  ?

• G06T 19/20 - Édition d'images tridimensionnelles [3D], p. ex. modification de formes ou de couleurs, alignement d'objets ou positionnements de parties
• G06T 7/00 - Analyse d'image
• G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
• G06T 7/90 - Détermination de caractéristiques de couleur
• G06T 11/00 - Génération d'images bidimensionnelles [2D]
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition

Abrégé

The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, comprising at least four distinct nucleic acid sequences encoding HPV antigens, to a lentiviral vector particle comprising said vector, to an isolated cell comprising the same, and to a vaccine composition comprising the said lentiviral vector, lentiviral vector particle or cell. The present invention further relates to their implementation in the treatment or prevention of an HPV induced cancer.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to the discovery that TMPRSS2 acts as a functional receptor for HKU1. TMPRSS2 triggers HKU1 spike-mediated cell-cell fusion and viral pseudotype infection. Catalytically inactive TMPRSS2 mutants do not cleave spike but allow infection, demonstrating that HKU1 binding and processing represent two distinct functions of the receptor. TMPRSS2 binds with high affinity to HKU1 receptor binding domain (RED), but neither to OC43 nor to SARS-CoV-2. Conserved amino acids were identified within the RED that are essential for binding to TMPRSS2 and infection. Anti- TMPRSS2 VHH antibodies were generated that inhibit HKU1 spike binding to TMPRSS2, fusion and infection.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Nanoparticles comprising an antiretroviral drug such as AZT-TP or enfuvirtide encapsulated by a complex of chitosan and optionally a metal cation such as Fe3+, for use in treating or preventing HIV infection via subcutaneous or intramuscular administration. The nanoparticles have a size less than 300 nm and a high drug loading capacity between 20-60% by weight. They are prepared by mixing an aqueous solution of chitosan and metal cation with an aqueous solution of the drug. The chitosan-based nanoparticles provide an effective method to deliver antiretroviral drugs to key HIV reservoir sites with high drug loading and low toxicity.

Classes IPC  ?

• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif
• A61P 31/12 - Antiviraux

Abrégé

The invention relates to an isolated heterodimer of poxvirus A16 and G9 proteins as an immunogen in a subunit or nucleic acid vaccine against poxvirus. The invention provides an engineered heterodimer, nucleic acid encoding the heterodimer, neutralizing antibodies directed against said heterodimer and their use for the prevention, treatment and diagnostics of poxvirus infections and related diseases.

Classes IPC  ?

• A61K 39/285 - Virus de la vaccine ou virus de la variole
• C07K 14/07 - Virus de la vaccineVirus de la variole
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

A computer-implemented and a device for analysis of a digital cytology slide of a biological sample. The biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, the device including: at least one input configured to receive at least one digital cytology slide obtained from the biological sample; at least one processor configured to: detect cells of interest from the at least one digital cytology image; for each cell of interest, compute a features vector including at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for the subject; at least one output configured to provide the global prediction score.

Classes IPC  ?

• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
• G06T 7/00 - Analyse d'image

Abrégé

This invention thus relates to a computer-implemented and a device for analysis of a digital cytology slide of a biological sample, said biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, said device comprising: at least one input configured to receive at least one digital cytology slide obtained from said biological sample; at least one processor configured to: detect cells of interest from said at least one digital cytology image; for each cell of interest, compute a feature vector comprising at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for said subject; at least one output configured to provide said global prediction score.

Classes IPC  ?

• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06T 7/00 - Analyse d'image
• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires

Abrégé

The present invention relates to novel tumor specific peptides derived from the translated ORF sequence from long noncoding RNA (lncRNA), and the uses thereof. The invention more particularly relates to the use of tumor specific peptides in cancer vaccines and cell therapy.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The present invention relates to a recombinant protein comprising one or more fragments of pneumococcal surface protein A (PspA) and the adenylate cyclase (CyaA) from Bordetella species, especially Bordetella pertussis, wherein said PspA fragments are selected from clades 1 to 4, or a combination of two or more thereof. Additionally, the invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, especially a DNA sequence selected from the group consisting of nucleotide sequences as set forth in SEQ ID NOs: 12 to 18 and degenerate sequences thereof that encode a recombinant protein as set forth in SEQ ID NOs: 5 to 11 respectively. Further, an immunogenic composition comprising said recombinant protein or said expression cassette, and additionally a pharmaceutically acceptable carrier and/or adjuvant is disclosed. Finally, the invention relates to the use of said recombinant protein, or said expression cassette, or said immunogenic composition for the manufacture of a vaccine for preventing infections caused by Streptococcus pneumoniae, wherein said vaccine offers broad-spectrum protection against different pneumococcal isolates, regardless of serotypes.

Classes IPC  ?

• C07K 14/235 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bordetella (G)
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

System for detecting an antigen comprising: —a first fusion protein with no luciferase activity comprising: —a N-terminal domain which comprises a first single domain antibody which is directed against a first epitope of said antigen and —a C-terminal domain which comprises a first fragment of a luciferase having the amino acid sequence SEQ ID NO: 1 or is a variant thereof and —a second fusion protein with no luciferase activity comprising: —a N-terminal domain which comprises a second single domain antibody which is directed against a second epitope of said antigen and —a C-terminal domain which comprises a second fragment of a luciferase having the amino acid sequence SEQ ID NO: 2 or is a variant thereof. Luminescence is emitted in the presence of a substrate when both the first fusion protein and the second fusion protein bind to said antigen.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

Classes IPC  ?

• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The invention relates to combined antibodies against Sarbecoviruses, in particular Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS- CoV-2).

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COV-ID-19).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The present invention further relates to the use of said AAV vector in the treatment of genetic hearing loss.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 15/86 - Vecteurs viraux
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention relates to in vitro generation of organized 3D cell structures recapitulating various degrees of early organogenesis, including head-trunk embryo-like structures, using epigenetic remodeling factors. The invention relates in particular to methods of obtaining such organized 3D cell structures from mammalian cells, and to devices, in particular microfluidic platform, to perform such methods. The invention also concerns the use of the thus obtained 3D cell structures in applications of molecule screening, developmental testing, production of physiologically active substances and models for therapeutic investigation or use.

Classes IPC  ?

• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• A61K 35/54 - OvairesOvules fécondésOvulesEmbryonsCellules fœtalesCellules germinales
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and/or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a single domain antibody directed against H2AX with a phosphorylation of serine at position 139 (γ-H2AX), a bivalent molecule comprising said single domain antibody and their use for detecting DNA damage and/or DNA replication stress.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

Classes IPC  ?

• C07K 5/087 - Tripeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p. ex. Phe, Tyr
• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

Classes IPC  ?

• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)

Abrégé

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The invention relates to the potentiation of aminoglycosides through activation of carbohydrate transporters, in particular using nucleosides. The invention encompasses the combination of a nucleoside and an aminoglycoside antibiotic for treating a bacterial infection, wherein the nucleoside enhances the killing of the bacteria by the antibiotic, preferably wherein the nucleoside limits the emergence of antibiotic-resistant bacteria or re-sensitizes antibiotic-resistant bacteria to the killing by the antibiotic.

Classes IPC  ?

• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 31/708 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique ayant des groupes oxo liés directement au système cyclique purine, p. ex. guanosine, acide guanylique
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.

Classes IPC  ?

• C12N 15/73 - Systèmes d'expression utilisant des séquences régulatrices du phage lambda
• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61P 31/04 - Agents antibactériens
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora

Abrégé

The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• C07D 487/04 - Systèmes condensés en ortho
• G01N 21/76 - ChimioluminescenceBioluminescence
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes

Abrégé

The present invention provides cationic peptoid/N-substituted peptidic copolymers, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful for the treatment of microbial infections.

Classes IPC  ?

• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61L 27/22 - Polypeptides ou leurs dérivés
• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The invention relates to a bacterial strain or a combination of bacterial strains, selected from the group consisting of: a Chryseobacterium massiliae strain, a Flavobacterium sp. strain with at least 95% or more Average Nucleotide Identity (ANI) value with the Flavobacterium sp. strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the Collection Nationale De Culture De Microorganismes (CNCM) on Jan. 24, 2020, and variants thereof, for use as a probiotic in fish(es). The bacterial strain(s) may has(ve) at least 95% or more Average Nucleotide Identity (ANI) value with the Chryseobacterium massiliae strain whose genome comprises SEQ ID NO:2 or as identified by Accession Number No. I-5479 deposited at the CNCM on Jan. 24, 2020, and/or the Flavobacterium sp. strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the CNCM on Jan. 24, 2020, respectively, or variants thereof. Probiotic use may be directed to preventing or minimizing infections by Flavobacterium columnare in fishes. The invention also concerns the said deposited bacterial strains, or probiotic compositions or food products or kits comprising the same, and a method to identify bacterial strain(s) that are probiotic against a pathogen infection.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
• A23K 50/80 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux aquatiques, p. ex. pour les poissons, les crustacés ou les mollusques
• C12N 1/20 - BactériesLeurs milieux de culture
• C12R 1/01 - Bactéries ou actinomycètes
• C12R 1/20 - Flavobacterium

Abrégé

Provided are methods comprising expressing in a recombinant cell a recombinant error-prone reverse transcriptase (RT) and recombinant spacer RNA comprising a target sequence; making a mutagenized cDNA polynucleotide homologous to a DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising a target sequence, and recombinant recombineering system.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12R 1/19 - Escherichia coli

Abrégé

The invention relates to compositions and methods for producing and using antibodies against the αlpha7 nicotinic acetylcholine receptor.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-pYP5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2-Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).

Classes IPC  ?

• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 31/12 - Antiviraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The invention relates to variants of a DNA polymerase of the polX family capable of synthesizing a nucleic acid molecule without a template strand, or of a functional fragment of such a polymerase, comprising at least one mutation of a residue in at least one specific position, and to uses of said variants, in particular for the synthesis of nucleic acid molecules comprising 3′-OH modified nucleotides.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides

Abrégé

The present invention relates to a bacterial exopolysaccharide having a repeating structure comprising a series of repeating units represented by formula (I), and to the use of the bacterial exopolysaccharide for immunopotentiation. (In formula (I), n represents an integer of 0 or 1, independently for each repeating unit.)

Classes IPC  ?

• C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61P 37/04 - Immunostimulants
• C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

Classes IPC  ?

• A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
• C07K 14/15 - Rétroviridae, p. ex. virus de la leucémie bovine, virus de la leucémie féline, virus de la leucémie lymphoïde des lymphocytes-T humains
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (FcγRs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human FcγRs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human FcγRs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated. These variants did not induce anaphylaxis when injected into mice expressing human FcγRs and could be thus used for the treatment of IgE-mediated disease. Thus invention relates to a recombinant immunoglobulin heavy chain protein which comprises at least one mutation in the Fc portion and recombinant antibody comprising said heavy chain protein.

Classes IPC  ?

• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Provided are methods comprising expressing in a recombinant cell comprising a Cas gene a recombinant error-prone reverse transcriptase (RT) and a recombinant spacer RNA comprising a target sequence for mutagenesis of a DNA sequence in the Cas gene; making a mutagenized cDNA polynucleotide homologous to the DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence of the Cas gene in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant Cas protein, recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising the target sequence, and recombinant recombineering system.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12N 9/22 - Ribonucléases
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

Pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase. Compositions or kits comprising the pseudotyped lentiviral vector particles and a mammalian cell expressing an Angiotensin-converting Enzyme 2 (ACE2) protein. Methods of assaying for the presence of neutralizing antibodies against a SARS-CoV-2 S protein in a sample comprising antibodies by providing pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase; providing mammalian cells expressing an ACE2 protein; contacting the mammalian cells expressing the ACE2 protein with the pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein in the presence of a sample comprising antibodies; and assaying for the presence of a label in the mammalian cells.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• C12N 15/86 - Vecteurs viraux
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées

Abrégé

The invention relates to an in vitro method of determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, comprising screening a biological sample of blood or plasma, where the level of at least two biomarkers selected amongst: PGK1, CFP, IGFALS, KRT19, SPRR1A, CPA4, CA2, SERPINA5, MAN2A1, KIF20B, SPEN, JUP, KRT6C, CDSN, KPRP, F13A1, SAA1 (SAA2), LBP, DSP, KRT2, KRT14, ARG1, S100A12, ATAD3B, MAN1A1, HAL, DCD, 07, HP, LEP, IL-8, IL-17, TNF-alpha, USF1, USF2, SELE, MSLN, EGFR, STATS and mtDNA level is determined, with the proviso that the selected biomarkers do not consist of the association of IL-8 and mtDNA level. The method may be for assessing the risk that a human patient has a non-atrophic gastritis (NAG), or an atrophic gastritis/pre-neoplasia (AG/P), or a gastric cancer (GO), or for discriminating between those risks or presence of these conditions. In a particular aspect, the method may comprise as a distinct, simultaneous or parallel step, a step of detecting an Helicobacter pylori infection. The invention also relates to a kit suitable for carrying out such a method, or a set of markers, and the use of the same for determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, or for prognosing or diagnosing a gastric pre-cancer condition or a gastric cancer condition.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present invention proposes a gene therapy approach as a potential curative treatment for the USHER syndrome, in particular for the USH1G syndrome, which is characterized by a profound deafness and a severe vestibular defect in humans. More precisely, the present invention concerns a gene therapy involving administering a vector expressing a SANS protein in a time window that is compatible with human ethics and welfare i.e., in post-natal, infant and adult humans in which the auditory system is completed. The present inventors herein show for the first time that it is possible to restore genetically-impaired auditory and vestibular functions in human beings in subjects suffering from an Usher1G syndrome even when the therapeutic vector is administered at this late stage.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 27/16 - Otologiques

Abrégé

The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.

Classes IPC  ?

• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, or a lentiviral vector particle, in particular a non-integrative lentiviral vector particle, for use for use in the treatment or prevention of an HPV induced cancer, the lentiviral vector comprising at least four distinct nucleic acid sequences; the lentiviral vector particle comprising at least one of the lentiviral vector; the lentiviral vector or the lentiviral vector particle being administered in combination with at least one immune checkpoint inhibitor.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/86 - Vecteurs viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention allows a rapid and early diagnosis of bacterial or viral infection. Such a diagnosis is highly desired among patients admitted in emergency department to allow the initiation of the appropriate treatment. Although no biomarker alone can offer an appropriate diagnosis with sufficient sensitivity and specificity, the present invention defines optimal combinations of biomarkers allowing the diagnosis of infection.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

This disclosure provides proteins, DNA, and dsRNA to improve host-induced gene silencing (HIGS) and spray-induced gene silencing (SIGS) in plant/insect systems, by applying to said plants a composition inducing in same the expression of an Hsc70-4 protein, preferably of a Drosophila melanogaster Hsc70-4 protein.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique

Abrégé

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps